# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Emily Dickinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI023-SYN-TD
- Date: 1885-06-01
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lucinda Hartwell, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month kidney and blood pressure review at home. **S**

## History of present illness

Ms. Dickinson is seen at home six weeks after her gastroenteritis. The repeat metabolic panel planned for two to three days after the sick visit was not drawn: she felt better by the second day and asked the phlebotomy service not to come. After a nurse call she restarted losartan, dapagliflozin, and amlodipine on the third day, once she had eaten and drunk normally for 24 hours. She has felt well since. Her home blood pressure averages 122/76. She has had no headaches for six weeks, sleeps about seven hours, and is writing full mornings. She has had no ankle swelling on amlodipine and no lightheadedness. She keeps the sick-day card in her medicine cabinet. **S**

| Element | Detail |
|---|---|
| Interval illness | Viral gastroenteritis six weeks ago with a prerenal creatinine rise; recovered |
| Missed check | Metabolic panel planned for two to three days after the sick visit was not drawn |
| Medicines | Restarted on the third day after a nurse call; taken daily since |
| Home blood pressure | Average 122/76 mmHg |
| Symptoms | No headaches for six weeks; sleeping about seven hours; no ankle swelling |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No nausea, vomiting, or diarrhea since recovery |
| Cardiovascular | Negative | No ankle swelling, palpitations, or lightheadedness |
| Neurological | Negative | No headaches for six weeks |
| Psychiatric | Negative | Mood good; PHQ-9 3 |

4 systems reviewed. **S**

## Current medications

- Losartan 100 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**
- Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth daily **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day **S**
- Dapagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Amlodipine 5 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/76 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 53.2 kg; BMI 20 kg/m². All vital signs are synthetic.

Sodium: 140 mmol/L; Potassium: 4.7 mmol/L; Bicarbonate (total CO2): 24 mmol/L; BUN: 22 mg/dL (high); Creatinine: 1.3 mg/dL (high); eGFR: 49 mL/min/1.73 m² (low); Glucose: 91 mg/dL; Urine albumin-creatinine ratio: 118 mg/g (high); PHQ-9: 3. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.7 mmol/L at this visit **S**
- Bicarbonate (total CO2): 24 mmol/L at baseline, 24 mmol/L at this visit **S**
- BUN: 21 mg/dL at baseline, 22 mg/dL (high) at this visit **S**
- Creatinine: 1.2 mg/dL (high) at baseline, 1.3 mg/dL (high) at this visit **S**
- eGFR: 54 mL/min/1.73 m² (low) at baseline, 49 mL/min/1.73 m² (low) at this visit **S**
- Glucose: 92 mg/dL at baseline, 91 mg/dL at this visit **S**
- Urine albumin-creatinine ratio: 240 mg/g (high) at baseline, 118 mg/g (high) at this visit **S**
- PHQ-9: 6 at baseline, 3 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine, CpG-adjuvanted (HepB-CpG), dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well, at her writing table |
| Cardiovascular | Regular rhythm; no murmur; no ankle edema |
| Mouth | Moist mucous membranes |
| Mental status | Alert and engaged; mood "well"; reactive affect |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic kidney disease G3a A2** (N18.31). Creatinine 1.30 mg/dL (eGFR 49) and potassium 4.7 mmol/L, back to her treated baseline after the gastroenteritis. The urine albumin-creatinine ratio has fallen from 240 to 118 mg/g, about half, on losartan and dapagliflozin. **S**
   - Continue losartan 100 mg and dapagliflozin 10 mg.
   - eGFR, urine albumin, calcium, phosphate, PTH, and vitamin D at the six-month review.
   - Hepatitis B vaccine dose 1 given today; dose 2 at least four weeks from now.
2. **Gastroenteritis with a prerenal creatinine rise, resolved** (A08.4). Recovered; kidney function back to baseline. **S**
   - Sick-day card reviewed; after any future kidney injury, the recheck will be booked before the clinician leaves.
3. **Hypertension with chronic kidney disease** (I12.9). 124/76 mmHg at home today; home average 122/76, close to the KDIGO systolic target. **S**
   - Continue losartan, amlodipine 5 mg, and low-salt diet.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Metabolic panel two to three days after the prerenal creatinine rise | Within days after acute kidney injury or a sick-day pause | Deferred | Not drawn, a deviation from the plan: she felt better on the second day and declined the home draw, and the medicines were restarted after a nurse call without a recheck. No harm, judging by today's creatinine of 1.30 mg/dL and potassium of 4.7 mmol/L. Corrective action: after any kidney injury, the recheck is booked as a firm home draw before the clinician leaves, and the nurse confirms it was done before advising a restart |
| Laboratory | Metabolic panel with each eGFR draw | With each eGFR draw; more often on an ARB or SGLT2 inhibitor | Completed today | Potassium 4.7 mmol/L, bicarbonate 24 mmol/L, creatinine 1.30 mg/dL, eGFR 49 |
| Laboratory | Urine albumin-creatinine ratio | Twice a year at G3a A2 (KDIGO heat map); about 3 months after starting treatment to judge response | Completed today | 118 mg/g, down about half from 240 |
| Examination | Standardized office and home blood pressure | Every visit | Completed today | 124/76 mmHg at the home visit; home average 122/76 |
| Examination | Weight and cardiac auscultation | Every visit | Completed today | 53.2 kg; regular rhythm; no edema on amlodipine |
| Survey | PHQ-9 | Yearly with hypertension; repeat if symptoms change | Completed today | 3, down from 6 as headaches and sleep improved |
| Medication safety | Medication review: NSAID avoidance, sick-day rules, and SGLT2 inhibitor safety | Every visit | Completed today | No NSAIDs; no genital or urinary symptoms; sick-day card in place |
| Medication safety | Vaccination review | Yearly in chronic kidney disease | Completed today | HepB-CpG dose 1 given today; PCV20 in January; influenza due in the autumn |
| Laboratory | Calcium, phosphate, PTH, and 25-hydroxyvitamin D | Every 6 to 12 months at G3a; vitamin D repeated after repletion | Due | At the six-month review, about eight months after baseline |
| Self-management | Sodium, activity, and home readings | Every visit | Completed today | Low-salt cooking; garden work most afternoons; weekly home readings |

## Goal progress

- Systolic blood pressure below 120 mmHg (KDIGO), and at least below 130/80, without lightheadedness. In progress; target 1885-09-28. **S**
- Urine albumin-creatinine ratio down by at least 30 percent from baseline on an ARB and an SGLT2 inhibitor. Outcome by 1885-06-01: 118 mg/g at three months and 96 mg/g at six months, from 240 mg/g. **S**
- Stable kidney function, with no fall in eGFR of more than 20 percent after the expected early dip. In progress; target 1885-09-28. **S**
- 25-hydroxyvitamin D of at least 30 ng/mL. In progress; target 1885-09-28. **S**
- Care delivered at home or by video wherever safe, with clinic trips limited to tests that need the clinic. In progress; target 1885-09-28. **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney Int 2024;105(4S):S117-S314)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney Int 2021;99(3S):S1-S87)
- 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017), American College of Cardiology and American Heart Association (Hypertension 2018;71(6):e13-e115)
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026), Aether Forge

## Follow-up

- Video visit in about four months with home vital signs and home blood and urine tests. **S**
- Next scheduled visit 1885-09-28: video visit for the six-month kidney review, with home vital signs and home blood tests. **S**
